Clinical trial
SB-742457 And Donepezil In Alzheimer's Disease
NCT00348192 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00348192 |
|---|---|
| Title | SB-742457 And Donepezil In Alzheimer's Disease |
| Official title | A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | SB-742457, donepezil |
| Enrollment | 200 |
| Start date | May 1, 2006 |
| First posted | Jul 4, 2006 |
| Last update posted | Jun 2, 2009 |
| Countries | Austria, Bulgaria, Chile, Estonia, Germany, Russia, Slovakia, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: